Bookmark and Share
BioAssay: AID 588768

Late stage assay provider results from the probe development effort to identify inhibitors of plasma platelet activating factor acetylhydrolase (pPAFAH): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds

Name: Late stage assay provider results from the probe development effort to identify inhibitors of plasma platelet activating factor acetylhydrolase (pPAFAH): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(3)
 
 
Active(2)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(3)
 
 
Active(2)
 
 
Inactive(1)
 
 
AID: 588768
Data Source: The Scripps Research Institute Molecular Screening Center (293TCYTOX_INH_ABSORB_5XCC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2011-11-03
Hold-until Date: 2012-05-31
Modify Date: 2012-05-31

Data Table ( Complete ):           Active    All
BioActive Compounds: 2
Depositor Specified Assays
AIDNameTypeProbeComment
463082Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)screening Primary screen (pPAFAH inhibitors in singlicate)
463092Summary of probe development efforts to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)summary1 Summary (pPAFAH inhibitors)
463230Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH; PLA2G7)screening Confirmation screen (pPAFAH inhibitors in triplicate)
588474Late stage assay provider results from the probe development effort to identify inhibitors of plasma platelet activating factor acetylhydrolase (pPAFAH): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of pPAFAHother ABPP Screen (pPAFAH inhibitors in singlicate)
588817Late stage assay provider results from the probe development effort to identify inhibitors of pPAFAH: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of pPAFAH in situother
588823Late stage assay provider results from the probe development effort to identify inhibitors of pPAFAH: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of pPAFAH and selectivity analysis in vivoother
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Providers: Brian Bahnson (Univ. of Delaware); Benjamin Cravatt, (TSRI)
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1R01HL084366
Grant Proposal PI: Brian Bahnson
External Assay ID: 293TCYTOX_INH_ABSORB_5XCC50

Name: Late stage assay provider results from the probe development effort to identify inhibitors of plasma platelet activating factor acetylhydrolase (pPAFAH): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds.

Description:

This project aims to develop specific inhibitors of plasma platelet activating factor acetylhydrolase (pPAFAH), and three associated members of the serine hydrolase family of enzymes-PAFAH2, PAFAH1b2, and PAFAH1b3. pPAFAH, an enzyme linked to the inflammatory pathways involved in atherosclerosis, asthma, anaphylactic shock, and other allergic reactions (1,2), is a lipoprotein-associated group VIIA phospholipase A2 that reduces the levels of the signaling molecule platelet activating factor (PAF) (3,4), a potent pro-inflammatory phospholipid signaling molecule (5), and other pro-inflammatory agents, such as oxidized phospholipids, through hydrolysis. A large number of studies have been published over the years since pPAFAH was first discovered linking an increase in pPAFAH concentration and/or activity to an increased risk of various cardiovascular diseases (6,7). The biological function of pPAFAH in the development of coronary heart diseases (CHD) is controversial, with both anti- and pro-inflammatory roles attributed to it (8,9). Dr. Bahnson and colleagues recently reported the first high-resolution crystal structure of the pPAFAH enzyme (10), and would like to expand their studies to co-crystallize pPAFAH with substrate-mimetic inhibitors to further define the active site and substrate specificity of pPAFAH. While one selective pPAFAH inhibitor has been reported (11), its properties are not suitable for the proposed studies. Given the complex biology of the pPAFAH enzymes, a complete characterization of their patho/physiological roles in lipid metabolism is necessary to maximize the success of therapeutic intervention. Towards this goal, development of selective inhibitors would significantly advance our understanding of these enzymes' substrate specificity and contribution to inflammatory disease processes including atherosclerosis, asthma, and rheumatoid arthritis. Pan-PAFAH inhibitors might be of heightened therapeutic value.

References:

1. Karasawa, K., Harada, A., Satoh, N., Inoue, K., and Setaka, M. (2003) Plasma platelet activating factor-acetylhydrolase (PAF-AH), Prog Lipid Res 42, 93-114.
2. Leitinger, N. (2005) Oxidized phospholipids as triggers of inflammation in atherosclerosis, Molecular Nutrition & Food Research 49, 1063-1071.
3. Blank, M. L., Lee, T., Fitzgerald, V., and Snyder, F. (1981) A specific acetylhydrolase for 1-alkyl-2- acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid), J Biol Chem 256, 175-178.
4. Farr, R. S., Cox, C. P., Wardlow, M. L., and Jorgensen, R. (1980) Preliminary studies of an acid labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF), Clin Immunol Immunopathol 15, 318-330.
5. Zimmerman, G. A., McIntyre, T. M., Prescott, S. M., and Stafforini, D. M. (2002) The plateletactivating factor signaling system and its regulators in syndromes of inflammation and thrombosis, Crit Care Med 30, S294-301.
6. Anderson, J. L. (2008) Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention, Am J Cardiol 101, 23F-33F.
7. Sudhir, K. (2005) Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease, J Clin Endocrinol Metab 90, 3100-3105.
8. Wilensky, R. L., and Macphee, C. H. (2009) Lipoprotein-associated phospholipase A(2) and atherosclerosis, Curr Opin Lipidol 20, 415-420.
9. Karabina, S. A., and Ninio, E. (2006) Plasma PAF-acetylhydrolase: an unfulfilled promise?, Biochim Biophys Acta 1761, 1351-1358.
10. Samanta, U., and Bahnson, B. J. (2008) Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis, J Biol Chem 283, 31617-31624.
11. Blackie, J. A., Bloomer, J. C., Brown, M. J. B., Cheng, H. Y., Hammond, B., Hickey, D. M. B., Ife, R. J., Leach, C. A., Lewis, V. A., Macphee, C. H., Milliner, K. J., Moores, K. E., Pinto, I. L., Smith, S. A., Stansfield, I. G., Stanway, S. J., Taylor, M. A., and Theobald, C. J. (2003) The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A(2), Bioorganic & Medicinal Chemistry Letters 13, 1067-1070.

Keywords:

late stage, late stage AID, assay provider, low throughput, secondary, PLA2G7, pPAFAH, serine hydrolase, platelet activating factor acetylhydrolase, inflammation, atherosclerosis, powders, fluorescence, competitive activity-based protein profiling, ABPP, gel-based, inhibitor, cytotoxicity, rhodamine-conjugated fluorophosphonate, FP-Rh, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Assays
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Serum-free medium21
2Serum-containing medium3

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of powder samples of synthetic inhibitor compounds belonging to the carbamate scaffold. In this assay, 293T Hek cells in either serum-free media (Assay 1) or media containing fetal calf serum (FCS) (Assay 2) are incubated with test compounds, followed by determination of cell viability. The assay utilizes the WST-1 substrate which is converted into colorimetric formazan dye by the metabolic activity of viable cells. The amount of formed formazan directly correlates to the number of metabolically active cells in the culture. As designed, compounds that reduce cell viability will result in decreased absorbance of the dye. Compounds were tested in a 7-point 1:5 dilution series starting at a nominal test concentration of 50 uM (n = 5 per concentration).

Protocol Summary:

This assay was started by dispensing 293T Hek cells in DMEM media (100 uL, 15,000 cells/well) into a 96-well plate. Both serum-free media (Assay 1) and media supplemented with 10% FCS (Assay 2) were tested. Compound (10 uL of 11x stocks in media containing 10% DMSO) was added to each well, giving final compound concentrations of 0-50 uM (7-point 1:5 dilution series). Cells were incubated for 48 hours at 37 C in a humidified incubator and cell viability was determined by the WST-1 assay (Roche) according to manufacturer instructions.


%_Cell_Viability = ( ABS_Test_Compound - Median_ABS_Low_Control ) / ( Median_ABS_High_Control - Median_ABS_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

For each test compound, percent inhibition was plotted against the log of the compound concentration. A three parameter equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc). The software-generated CC50 values are reported.

PubChem Activity Outcome and Score:

The following applies to each panel in this assay:

Compounds with CC50 less than or equal to 5 uM were considered active (cytotoxic). Compounds with CC50 greater than 5 uM were considered inactive (non-cytotoxic).

Any compound with a percent activity value less than 50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value greater than or equal to 50% at any test concentration was assigned an activity score greater than zero.

Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

Serum-free medium Score: The PubChem Activity Score range for active compounds is 100-74, and for inactive compounds 1-1.

Serum-containing medium Score: The PubChem Activity Score range for inactive compounds is 100-1. There are no active compounds.

Overall Outcome and Score:

The overall outcome was active if the compound was active in at least one panel, inactive otherwise.

The overall score is 0 if the compound was inactive, otherwise the score is taken as the fraction of panels where the compound is active, multiplied by 100.

The PubChem Activity Score range for active compounds is 50-50, and for inactive compounds 0-0.

List of Reagents:

293T Hek cells (provided by Assay Provider)
DMEM Media (CellGro 10-017-CV)
FCS (Omega Scientific, FB-01)
WST-1 reagent (Roche)
96-well plates (Corning)
Comment
This assay was performed by the assay provider with powder samples of synthesized test compounds.
Categorized Comment
BAO: version: 1.4b1090

BAO: bioassay specification: assay stage: secondary: alternate confirmatory

BAO: bioassay specification: assay biosafety level: bsl1

BAO: assay format: biochemical format: protein format: single protein format

BAO: bioassay specification: assay measurement type: endpoint assay

BAO: bioassay specification: assay readout content: assay readout method: regular screening

BAO: bioassay specification: assay readout content: content readout type: single readout

BAO: meta target: molecular target: protein target: enzyme: generic hydrolase

BAO: meta target detail: binding reporter specification: interaction: protein-small molecule

BAO: detection technology: fluorescence: fluorescence intensity

Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Outcome [Serum-free]One of Active, Inactive, or Not Tested1Outcome
2Score [Serum-free]The BioAssay score.1Integer
3CC50 [Serum-free]*The value for the concentration at which 50% of surviving cells are observed in serum-free medium; CC50 shown in micromolar.1FloatμM
4Surviving Cells at 50 uM [1] [Serum-free] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-free medium; replicate[1]1Float%
5Surviving Cells at 50 uM [2] [Serum-free] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-free medium; replicate[2]1Float%
6Surviving Cells at 50 uM [3] [Serum-free] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-free medium; replicate[3]1Float%
7Surviving Cells at 50 uM [4] [Serum-free] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-free medium; replicate[4]1Float%
8Surviving Cells at 50 uM [5] [Serum-free] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-free medium; replicate[5]1Float%
9Surviving Cells at 10 uM [1] [Serum-free] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-free medium; replicate[1]1Float%
10Surviving Cells at 10 uM [2] [Serum-free] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-free medium; replicate[2]1Float%
11Surviving Cells at 10 uM [3] [Serum-free] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-free medium; replicate[3]1Float%
12Surviving Cells at 10 uM [4] [Serum-free] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-free medium; replicate[4]1Float%
13Surviving Cells at 10 uM [5] [Serum-free] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-free medium; replicate[5]1Float%
14Surviving Cells at 2 uM [1] [Serum-free] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-free medium; replicate[1]1Float%
15Surviving Cells at 2 uM [2] [Serum-free] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-free medium; replicate[2]1Float%
16Surviving Cells at 2 uM [3] [Serum-free] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-free medium; replicate[3]1Float%
17Surviving Cells at 2 uM [4] [Serum-free] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-free medium; replicate[4]1Float%
18Surviving Cells at 2 uM [5] [Serum-free] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-free medium; replicate[5]1Float%
19Surviving Cells at 0.4 uM [1] [Serum-free] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-free medium; replicate[1]1Float%
20Surviving Cells at 0.4 uM [2] [Serum-free] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-free medium; replicate[2]1Float%
21Surviving Cells at 0.4 uM [3] [Serum-free] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-free medium; replicate[3]1Float%
22Surviving Cells at 0.4 uM [4] [Serum-free] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-free medium; replicate[4]1Float%
23Surviving Cells at 0.4 uM [5] [Serum-free] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-free medium; replicate[5]1Float%
24Surviving Cells at 0.08 uM [1] [Serum-free] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-free medium; replicate[1]1Float%
25Surviving Cells at 0.08 uM [2] [Serum-free] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-free medium; replicate[2]1Float%
26Surviving Cells at 0.08 uM [3] [Serum-free] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-free medium; replicate[3]1Float%
27Surviving Cells at 0.08 uM [4] [Serum-free] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-free medium; replicate[4]1Float%
28Surviving Cells at 0.08 uM [5] [Serum-free] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-free medium; replicate[5]1Float%
29Surviving Cells at 0.016 uM [1] [Serum-free] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-free medium; replicate[1]1Float%
30Surviving Cells at 0.016 uM [2] [Serum-free] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-free medium; replicate[2]1Float%
31Surviving Cells at 0.016 uM [3] [Serum-free] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-free medium; replicate[3]1Float%
32Surviving Cells at 0.016 uM [4] [Serum-free] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-free medium; replicate[4]1Float%
33Surviving Cells at 0.016 uM [5] [Serum-free] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-free medium; replicate[5]1Float%
34Surviving Cells at 0.0032 uM [1] [Serum-free] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-free medium; replicate[1]1Float%
35Surviving Cells at 0.0032 uM [2] [Serum-free] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-free medium; replicate[2]1Float%
36Surviving Cells at 0.0032 uM [3] [Serum-free] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-free medium; replicate[3]1Float%
37Surviving Cells at 0.0032 uM [4] [Serum-free] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-free medium; replicate[4]1Float%
38Surviving Cells at 0.0032 uM [5] [Serum-free] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-free medium; replicate[5]1Float%
39Outcome [Serum]One of Active, Inactive, or Not Tested2Outcome
40Score [Serum]The BioAssay score.2Integer
41CC50 [Serum]*The value for the concentration at which 50% of surviving cells are observed in serum-containing medium; CC50 shown in micromolar.2FloatμM
42Surviving Cells at 50 uM [1] [Serum] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-containing medium; replicate[1]2Float%
43Surviving Cells at 50 uM [2] [Serum] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-containing medium; replicate[2]2Float%
44Surviving Cells at 50 uM [3] [Serum] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-containing medium; replicate[3]2Float%
45Surviving Cells at 50 uM [4] [Serum] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-containing medium; replicate[4]2Float%
46Surviving Cells at 50 uM [5] [Serum] (50μM**)Value of % surviving cells at at 50 uM compound concentration in serum-containing medium; replicate[5]2Float%
47Surviving Cells at 10 uM [1] [Serum] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-containing medium; replicate[1]2Float%
48Surviving Cells at 10 uM [2] [Serum] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-containing medium; replicate[2]2Float%
49Surviving Cells at 10 uM [3] [Serum] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-containing medium; replicate[3]2Float%
50Surviving Cells at 10 uM [4] [Serum] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-containing medium; replicate[4]2Float%
51Surviving Cells at 10 uM [5] [Serum] (10μM**)Value of % surviving cells at at 10 uM compound concentration in serum-containing medium; replicate[5]2Float%
52Surviving Cells at 2 uM [1] [Serum] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-containing medium; replicate[1]2Float%
53Surviving Cells at 2 uM [2] [Serum] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-containing medium; replicate[2]2Float%
54Surviving Cells at 2 uM [3] [Serum] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-containing medium; replicate[3]2Float%
55Surviving Cells at 2 uM [4] [Serum] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-containing medium; replicate[4]2Float%
56Surviving Cells at 2 uM [5] [Serum] (2μM**)Value of % surviving cells at at 2 uM compound concentration in serum-containing medium; replicate[5]2Float%
57Surviving Cells at 0.4 uM [1] [Serum] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-containing medium; replicate[1]2Float%
58Surviving Cells at 0.4 uM [2] [Serum] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-containing medium; replicate[2]2Float%
59Surviving Cells at 0.4 uM [3] [Serum] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-containing medium; replicate[3]2Float%
60Surviving Cells at 0.4 uM [4] [Serum] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-containing medium; replicate[4]2Float%
61Surviving Cells at 0.4 uM [5] [Serum] (0.4μM**)Value of % surviving cells at at 0.4 uM compound concentration in serum-containing medium; replicate[5]2Float%
62Surviving Cells at 0.08 uM [1] [Serum] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-containing medium; replicate[1]2Float%
63Surviving Cells at 0.08 uM [2] [Serum] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-containing medium; replicate[2]2Float%
64Surviving Cells at 0.08 uM [3] [Serum] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-containing medium; replicate[3]2Float%
65Surviving Cells at 0.08 uM [4] [Serum] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-containing medium; replicate[4]2Float%
66Surviving Cells at 0.08 uM [5] [Serum] (0.08μM**)Value of % surviving cells at at 0.08 uM compound concentration in serum-containing medium; replicate[5]2Float%
67Surviving Cells at 0.016 uM [1] [Serum] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-containing medium; replicate[1]2Float%
68Surviving Cells at 0.016 uM [2] [Serum] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-containing medium; replicate[2]2Float%
69Surviving Cells at 0.016 uM [3] [Serum] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-containing medium; replicate[3]2Float%
70Surviving Cells at 0.016 uM [4] [Serum] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-containing medium; replicate[4]2Float%
71Surviving Cells at 0.016 uM [5] [Serum] (0.016μM**)Value of % surviving cells at at 0.016 uM compound concentration in serum-containing medium; replicate[5]2Float%
72Surviving Cells at 0.0032 uM [1] [Serum] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-containing medium; replicate[1]2Float%
73Surviving Cells at 0.0032 uM [2] [Serum] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-containing medium; replicate[2]2Float%
74Surviving Cells at 0.0032 uM [3] [Serum] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-containing medium; replicate[3]2Float%
75Surviving Cells at 0.0032 uM [4] [Serum] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-containing medium; replicate[4]2Float%
76Surviving Cells at 0.0032 uM [5] [Serum] (0.0032μM**)Value of % surviving cells at at 0.0032 uM compound concentration in serum-containing medium; replicate[5]2Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1R01HL084366

PageFrom: